Innovative Dynabeads Alternative: Exploration AI
We are pioneering a novel approach at Exploration AI, where our focus lies in developing an innovative alternative to traditional dynabeads, using red blood cells. Our unique proposition capitalizes on leveraging the natural properties of these cells, which could revolutionize various processes in diagnosis and therapies, creating a more efficient and safer alternative in the medical and biotechnology sectors.
Our mission is to revolutionize precision medicine with scalable, sustainable, innovative cell-based solutions.
Academic and Clinical Research Labs and Biotechnology and Pharmaceutical Companies
This product solves the high cost, scalability, and environmental challenges associated with synthetic magnetic beads by offering a biodegradable, biocompatible, and cost-effective alternative using red blood cells. It enables more accessible and efficient solutions for research, diagnostics, and therapeutic applications, especially in resource-limited settings.
High cost, scalability, and environmental challenges associated with synthetic magnetic beads by offering a biodegradable, biocompatible, and cost-effective alternative using red blood cells.
Our solution is our innovative product called "Exploration AI," which uses red blood cells to create a bio-compatible, cost-effective alternative to synthetic magnetic beads. This not only addresses environmental concerns but also reduces costs and improves scalability for research, diagnostic, and
Artificial Intelligence, Machine Learning, Medical Imaging Technologies, Computational Biology.
Engineered red blood cells with surface modifications to bind specific targets, enabling efficient isolation, purification, or detection in research and clinical workflows.
We provide a cost-effective, scalable and sustainable cell-based solution that enhances the efficiency of diagnostics and therapies in resource-limited settings.
We estimate the market size for which our solution is designed in monetary terms as follows
Is our goal in the next 3 years
My key role is Executive and I'm responsible for strategic direction, fostering a culture of growth and innovation, and overseeing operations.
Consider including a Chief Financial Officer for financial strategy, a Sales Director to help drive revenue, and perhaps an HR Manager for team coordination.
Our main competitors are Dynal Biotech, Miltenyi Biotec, and Bio-Rad. They all offer cell isolation solutions similar to ours but struggle with cost-effectiveness and scalability. Other alternatives include high-cost methods like microfluidic cell sorting and optical tweezers.
Our product boasts an enhanced phenotype, offering maximum efficiency. It serves as a cost-effective solution, thereby significantly reducing the associated expenses and fostering economical operations.
Reagent kits
We've produced a compelling proof of concept, successfully demonstrating our product's potential. We're now adeptly leveraging data to optimize our solutions and design strategies for scale, consistently meeting key performance indicators.
Since our inception, we've made significant strides in developing a robust proof-of-concept. This has been pivotal in de-risking the business model. The outcomes have affirmed our potential scalability, preparing us for an imminent series funding round.
Our startup primarily focuses on product metrics like the growth rate (fold expansion), observable traits of cells grown in a laboratory environment (phenotypic characteristics), and consistency in their performance, expressed as percent coefficient variation (%CV).
Our startup is currently at the Series A stage, where we're busy strengthening our product and user base. Although we haven't started generating revenue yet, we are confident in the potential growth and profitability of our business model in the medium to long term.
Our company incorporated in
Texas
The primary risks include technological feasability, acceptance by the scientific community and regulatory complexities. Furthermore, any unforeseen health impacts might emerge during development or post-launch, potentially jeopardising adoption of our solution.
$
500000
We raised investments
Friends and family, 20 percent
$
5000000
Currently, we are raising investments
$
10000000
Estimated pre-investment valuation of the company
Upon completion of our Proof of Concept, we intend to undertake voice-of-customer research for further refinement and improvement.